المحتويات
Clinical, bacteriological and radiological monitoring is the same as for patients on DS-TB treatment (Chapter 9).
- If, after the patient has started the standard Hr-TB regimen:
- fluoroquinolone resistance is detected: perform a new RMT to rule out the emergence of resistance to rifampicin,
- pyrazinamide resistance is detected: perform a new RMT to rule out the emergence of resistance to rifampicin or fluoroquinolones.
- Biological monitoring is reinforced and includes the following tests:
- Patients on pyrazinamide: liver function tests at baseline, then once a month (risk of hepatotoxicity with prolonged use of pyrazinamide).
- Patients on ethambutol: Ishihara test (Appendix 16) and visual acuity test at baseline, then once a month (risk of visual toxicity with prolonged use of ethambutol).
- Patients on linezolid:
- Full blood count at baseline, every 2 weeks for the first 2 months, then once a month.
- Peripheral neuropathy screening (BPNS, Appendix 16) at baseline, then once a month.
- Ishihara test (Appendix 16) and visual acuity test at baseline, then once a month.